In a new AMP working group project, labs can volunteer to compare their interpretation of challenging variants to help identify where and how the guidelines might be improved.
One deal will see Philips' solution used to improve cancer patient outcomes while the other will beef up its ability to interpret data from oncology tests.
The company said it will use the funds to complete and launch Mastermind, its flagship product for analyzing and interpreting variant data.
The partners will co-market the GenomOncology GO Clinical Workbench to interpret data generated using Fluidigm's Juno NGS library prep workflow.
The combined products will provide customers with a comprehensive solution for managing next-generation sequencing workflows in the lab.
The company purchased Tute in a stock-based transaction that closed last month.
The platform features a more comprehensive list of pipelines, simplifies data movement and flow, and reduces analysis times.
HUG's genetic medicine arm will use Saphetor's software and variant knowledgebase in clinical projects focused on developmental and neurological disorders.
Using genome sequence data from almost 65,000 individuals, researchers identified 39.2 million SNPs that can be applied to improved genotyping imputation.
Companies vie to manage genomic data, the Economist reports.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.